HLA-DRA 抗体 (AA 28-254) (Biotin)
Quick Overview for HLA-DRA 抗体 (AA 28-254) (Biotin) (ABIN7155602)
抗原
See all HLA-DRA 抗体适用
宿主
克隆类型
标记
应用范围
-
-
抗原表位
- AA 28-254
-
交叉反应
- 人
-
纯化方法
- >95%, Protein G purified
-
免疫原
- Recombinant Human HLA class II histocompatibility antigen, DR alpha chain protein (28-254AA)
-
亚型
- IgG
-
-
anti-HLA Class II DR alpha (HLA-DRA) (AA 26-254) antibody
HLA-DRA 适用: 人 WB, FACS, ELISA, ICC 宿主: 小鼠 Monoclonal 1C11A5 unconjugated
anti-HLA Class II DR alpha (HLA-DRA) (AA 26-216) antibodyHLA-DRA 适用: 人 WB, IHC 宿主: 兔 Polyclonal unconjugated
anti-HLA Class II DR alpha (HLA-DRA) (AA 27-216) antibodyHLA-DRA 适用: 人 WB 宿主: 兔 Polyclonal unconjugated
anti-HLA Class II DR alpha (HLA-DRA) (AA 1-254) antibodyHLA-DRA 适用: 人 WB, IP 宿主: 兔 Polyclonal unconjugated
anti-HLA Class II DR alpha (HLA-DRA) antibodyHLA-DRA 适用: 人 IHC, FACS, IF, StM 宿主: 小鼠 Monoclonal 19-26-1-same as MB-26-1 unconjugated
anti-HLA Class II DR alpha (HLA-DRA) antibodyHLA-DRA 适用: 人, 大鼠, 小鼠 WB, IHC, ELISA, IF, ICC 宿主: 兔 Polyclonal unconjugated
anti-HLA Class II DR alpha (HLA-DRA) antibodyHLA-DRA 适用: 人 IHC 宿主: 兔 Monoclonal MSVA-470R unconjugated Recombinant Antibody
anti-HLA Class II DR alpha (HLA-DRA) (AA 26-221) antibody (APC)HLA-DRA 适用: 兔 WB, IHC 宿主: 豚鼠 Polyclonal APC
anti-HLA Class II DR alpha (HLA-DRA) antibodyHLA-DRA 适用: 人 IHC, ELISA 宿主: 兔 Polyclonal unconjugated
anti-HLA Class II DR alpha (HLA-DRA) antibodyHLA-DRA 适用: 人, Cow, Cat FACS, IF 宿主: 小鼠 Monoclonal 169-1B5-2 unconjugated
-
-
应用备注
- Optimal working dilution should be determined by the investigator.
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
缓冲液
-
Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4 -
储存液
- ProClin
-
注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
储存条件
- -20 °C,-80 °C
-
储存方法
- Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
-
- HLA-DRA (HLA Class II DR alpha (HLA-DRA))
-
别名
- HLA-DRA
-
背景
-
Background: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.
Aliases: DASS-397D15.1 antibody, DR alpha chain antibody, DR alpha chain precursor antibody, DRA_HUMAN antibody, DRB1 antibody, DRB4 antibody, FLJ51114 antibody, Histocompatibility antigen HLA DR alpha antibody, Histocompatibility antigen HLA-DR alpha antibody, HLA class II histocompatibility antigen antibody, HLA class II histocompatibility antigen DR alpha chain antibody, HLA DR1B antibody, HLA DR3B antibody, HLA DRA antibody, HLA DRA1 antibody, HLA DRB1 antibody, HLA DRB3 antibody, HLA DRB4 antibody, HLA DRB5 antibody, HLA-DR histocompatibility type antibody, HLA-DRA antibody, HLADR4B antibody, HLADRA1 antibody, HLADRB antibody, Major histocompatibility complex class II DR alpha antibody, Major histocompatibility complex class II DR beta 1 antibody, Major histocompatibility complex class II DR beta 3 antibody, Major histocompatibility complex class II DR beta 4 antibody, Major histocompatibility complex class II DR beta 5 antibody, MGC117330 antibody, MHC cell surface glycoprotein antibody, MHC class II antigen DRA antibody, MHC II antibody, MLRW antibody, OTTHUMP00000029406 antibody, OTTHUMP00000029407 antibody
-
UniProt
- P01903
-
途径
- TCR Signaling, CXCR4-mediated Signaling Events, Human Leukocyte Antigen (HLA) in Adaptive Immune Response
抗原
-
